Bioaffinity Technologies, Stock Alpha and Beta Analysis
| BIAF Stock | USD 1.20 0.02 1.64% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as bioAffinity Technologies,. It also helps investors analyze the systematic and unsystematic risks associated with investing in BioAffinity Technologies, over a specified time horizon. Remember, high BioAffinity Technologies,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BioAffinity Technologies,'s market risk premium analysis include:
Beta 0.85 | Alpha (0.39) | Risk 7.23 | Sharpe Ratio (0.02) | Expected Return (0.16) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BioAffinity |
BioAffinity Technologies, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BioAffinity Technologies, market risk premium is the additional return an investor will receive from holding BioAffinity Technologies, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BioAffinity Technologies,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BioAffinity Technologies,'s performance over market.| α | -0.39 | β | 0.85 |
BioAffinity Technologies, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BioAffinity Technologies,'s Buy-and-hold return. Our buy-and-hold chart shows how BioAffinity Technologies, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BioAffinity Technologies, Market Price Analysis
Market price analysis indicators help investors to evaluate how BioAffinity Technologies, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioAffinity Technologies, shares will generate the highest return on investment. By understating and applying BioAffinity Technologies, stock market price indicators, traders can identify BioAffinity Technologies, position entry and exit signals to maximize returns.
BioAffinity Technologies, Return and Market Media
The median price of BioAffinity Technologies, for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 1.55 with a coefficient of variation of 18.02. The daily time series for the period is distributed with a sample standard deviation of 0.29, arithmetic mean of 1.62, and mean deviation of 0.26. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | bioAffinity Technologies announces secondary offering of 1.8M shares | 09/12/2024 |
2 | Insider Trading | 09/16/2024 |
3 | Peer-Reviewed Study bioAffinity Technologies CyPath Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complica... | 09/18/2024 |
4 | bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test | 10/09/2024 |
5 | bioAffinitys CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines | 10/16/2024 |
6 | bioAffinity Technologies Announces Closing of 2.6 Million Registered Direct Offering Concurrent Private Placement | 10/21/2024 |
7 | Acquisition by Edwards James Michael of 100000 shares of BioAffinity Technologies, subject to Rule 16b-3 | 11/05/2024 |
8 | bioAffinity Technologies, Inc. Short Interest Update | 11/14/2024 |
9 | bioAffinity Technologies stock hits 52-week low at 1.21 - Investing.com | 11/21/2024 |
About BioAffinity Technologies, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BioAffinity or other stocks. Alpha measures the amount that position in bioAffinity Technologies, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.0209 | 0.001353 | 2.88 | 3.02 | Days Of Inventory On Hand | 5.4K | 4.3K | 3.88 | 3.68 |
BioAffinity Technologies, Upcoming Company Events
As portrayed in its financial statements, the presentation of BioAffinity Technologies,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioAffinity Technologies,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of BioAffinity Technologies,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of BioAffinity Technologies,. Please utilize our Beneish M Score to check the likelihood of BioAffinity Technologies,'s management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with BioAffinity Technologies,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out BioAffinity Technologies, Backtesting, BioAffinity Technologies, Valuation, BioAffinity Technologies, Correlation, BioAffinity Technologies, Hype Analysis, BioAffinity Technologies, Volatility, BioAffinity Technologies, History and analyze BioAffinity Technologies, Performance. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
BioAffinity Technologies, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.